He is the former Executive Partner of Watervein Partners. He has been Outside Director of KinoPharma since 2006 and was appointed CEO in December 2010.
He has experience in investing and incubating a number of biotech successful startups in Japan.
Ex-JST/START program promoter. He holds an MBA.
Head of Research and Development
After working as a researcher of CREST and NEDO, he became a Specially-appointed Research Associate of Kurokawa Laboratory at The Institute of Medical Sciences, Tokai University in 2003.
He founded KinoPharma and was appointed COO in 2005. Since then, as the Leader of Drug Discovery Program, he has been engaged in activities, ranging from platform technologies to development.
Head of Clinical Development
After engaging in discovery research at Chugai Pharmaceutical, he moved to the clinical development department, where he achieved approval of an osteoporosis drug, and was appointed General Manager of the department in 2008. His experience also covers the establishment of a clinical development organization at Chugai Joint Venture in South Korea. He holds a Ph.D.
(in charge of business strategy)
He had been engaged in drug discovery at Chugai Pharmaceutical. He changed his careers to venture capital and served as the Deputy General Manager of Life Science at Mitsubishi UFJ Capital. He served as a director of KinoPharma from 2016. He concurrently serves as a director of Kringle Pharma. He holds a PhD.
(in charge of research planning, quality assurance, and risk management)
He is the former director of Biology Research Institute, director of Safety Research Institute, and deputy director of Exploratory Research Institute at JT Pharmaceutical Department. He has an extensive experience, ranging from exploratory research to safety studies. He has a PhD.
He has been engaged in clinical development at Chugai Pharmaceutical. He was appointed as the Director of Clinical Development of Chugai Pharmaceutical in 2005. He was appointed President of Chugai Pharma Science (Beijing) in 2011 and has been served as an outside director of KinoPharma since January 2018.
After working at Deutsche Securities and TPG Capital, he joined Japan Growth Investments Alliance as a director (current position) in 2017. He has been serving as an outside director of KinoPharma since September 2018.